On March 15, 2018 Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported an upcoming poster presentation at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place from April 14-18, 2018 in Chicago, IL (Press release, Bio-Path Holdings, MAR 15, 2018, View Source [SID1234524805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Olivia D. Lara, University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology, will present preclinical data of prexigebersen (BP1001, liposomal Grb2 antisense), the Company’s lead drug candidate, for the treatment of gynecologic malignancies.

Details for the poster presentation are as follows:

Date: Wednesday, April 18, 2018

Presentation Time: 8:00 am – 12:00 pm Eastern Time

Location: McCormick Place, Chicago, Illinois

Session: Experimental and Molecular Therapeutics, Section 36

Abstract: 5786

Title: "Grabbing GRB2: The use of liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies" (Link to abstract)